Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou can drink alcohol while taking weight loss injections such as Mounjaro or Wegovy, but there are good clinical reasons to be cautious. Both medicines slow gastric emptying and reduce appetite, which changes how quickly alcohol enters your bloodstream and how hungry you feel before you drink. Neither carries an outright alcohol prohibition in the prescribing information, but the combination deserves more thought than most people give it. These are prescription-only medicines that a clinician must assess you for before you start, and alcohol is one of the lifestyle questions that prescribers routinely consider as part of that review.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most widespread piece of misinformation circulating online is that alcohol is completely banned the moment you start a GLP-1 weight loss injection. It is not. Neither the Mounjaro nor the Wegovy prescribing information lists alcohol as a contraindication. What both do, clearly, is slow the rate at which your stomach empties its contents into the small intestine. That mechanism is central to how these medicines reduce appetite, but it also reshapes how alcohol behaves in your body.
Because gastric emptying slows, alcohol can linger in the stomach longer before being absorbed, and then move into the bloodstream more abruptly. The practical result for many people is that a single glass of wine or a pint produces a stronger, faster effect than it would have done before they started treatment. That is not a reason to stop drinking entirely; it is a reason to be alert to the change and adjust accordingly. The NHS patient page for tirzepatide advises caution with alcohol rather than abstinence, which is a meaningfully different message.
A quick habit worth building: before your first drink on any given occasion, check whether you have eaten anything in the last three or four hours. On treatment, skipping meals becomes easier because hunger signals are quieter. Drinking on a near-empty stomach amplifies both the intoxicating effect and the risk of nausea. If you have not eaten, something light beforehand is worth the few minutes it takes.
Gastrointestinal side effects (nausea especially) are the most commonly reported experiences in the early weeks of treatment and after each dose increase. In the clinical trials for tirzepatide, nausea was reported by a significant proportion of participants at therapeutic doses; semaglutide trials showed a similar pattern, as documented in the STEP 1 study published in the New England Journal of Medicine. Alcohol is itself a gastrointestinal irritant. Combining the two during the period when your system is still adjusting to a new dose is a reliable way to make nausea considerably worse.
This matters practically because the weeks when nausea is most acute are also the weeks when the temptation to test your limits is highest. People feel the medicine working and assume the side effects have passed. Then a social occasion arrives and a couple of drinks later they feel far worse than expected. The advice from our clinical team at nume is consistent: if you have recently started treatment or moved to a higher dose, give your body two to three weeks to settle before you drink at all, and then start with less than you might usually choose.
Vomiting from combined nausea and alcohol also carries a dehydration risk that is worth taking seriously. If you are losing fluids through vomiting on any GLP-1 medicine, rehydration becomes urgent and you should contact your prescriber or seek medical advice rather than waiting to see how you feel.
For the majority of people on weight loss injections who do not have type 2 diabetes, the blood-sugar picture is less acute than it is for those on insulin or sulfonylureas. Still, both tirzepatide and semaglutide lower blood glucose as part of their mechanism, and alcohol independently suppresses the liver's ability to release stored glucose. Drinking while on either medicine (particularly without food) can push blood sugar lower than you might expect. Symptoms such as shakiness, unusual tiredness or feeling more confused than a small amount of alcohol would normally explain are worth noting.
Alcohol is also calorie-dense and tends to lower inhibitions around eating, which can quietly work against the reduced appetite that makes these medicines effective. There is no rule that says one glass of wine undoes your progress, but consistent heavy drinking creates a headwind. The NHS recommends that adults in general keep within 14 units per week spread across several days; on weight loss treatment, staying well under that ceiling and having alcohol-free days is the practical guidance that prescribers tend to echo. You can read more about the broader dietary context in our guidance on what to eat while on weight loss injections.
If you are also taking other medications (antihypertensives or cholesterol-lowering drugs are common alongside weight management treatment) alcohol can interact with those too. Your prescriber holds the full picture, which is one reason why the clinical review that comes with every repeat at nume covers lifestyle as well as weight data.
The sensible framework is graduated, not prohibitive. In the first four weeks of treatment, or for two to three weeks after a dose increase, keeping alcohol to a minimum (ideally none) gives your system the best chance of settling without added gastrointestinal stress. Once you are stable at a given dose and nausea has settled, moderate drinking is not off the table, but smaller amounts will likely have a more pronounced effect than before. For a detailed look at how this plays out day to day, the drinking on weight loss injections page covers specific scenarios.
Certain situations do call for a conversation before drinking rather than after. If you have liver disease, a history of pancreatitis, or you are taking medicines that interact with alcohol, those are prescriber-level questions. The same applies if you are wondering whether treatment is right for you at all given your current lifestyle: that is exactly what a free consultation is for. Understanding what weight loss injection treatment costs privately and what it includes is often the first practical question people ask, and our FAQs cover several of the surrounding details. The injection pens themselves, including storage and general use guidance, are covered in our injection pens for weight loss page.
Treatment for weight management is also not appropriate in all circumstances, including during pregnancy or breastfeeding, if either applies to you, the weight loss injections and pregnancy page explains the position clearly. If you have a specific concern not covered here, our team is reachable via the contact page. When you are ready to explore whether treatment is clinically suitable for you, check your eligibility with a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.